AMENDMENTS TO THE CLAIMS

Kindly amend the claims as follows:

In the claims:

1. (Presently Amended): A compound for inhibiting expression of angiogenin comprising an oligonucleotide or analog thereof having a base sequence complementary to a target portion of a nucleic acid encoding human angiogenin.

2. (Previously Amended): The compound of claim 1 wherein the base sequence binds to the target portion of the nucleic acid in a manner to inhibit the expression of angiogenin.

3. (Previously Amended): The compound of claim 2 wherein the oligonucleotide analog comprises a modification selected from the group consisting of a modified internucleotide linkage, a modified purine or pyrimidine moiety, a modified sugar moiety, a modified 5' hydroxyl moiety, a modified 3' hydroxyl moiety and a modified 2' hydroxyl moiety.

4. (Previously Amended): The compound of claim 3 wherein the modified internucleotide linkage comprises a substituent having an improved aqueous or lipid solubility or improved resistance to nuclease digestion as compared to an unmodified compound.

5. (Previously Amended): The compound of claim 4 wherein the modified internucleotide linkage is selected from the group consisting of phosphorothioate, N-alkyl phosphoramidates, cycloalkyl phosphoramidates, alkyl phosphonates, cycloalkyl phosphonates, phosphodiester, phosphotriester, C_1 - C_4 alkyl, cycloalkyl, short chain heteroatomic backbone, short chain heterocyclic backbone, morpholino backbone, polyprotein-nucleic acid backbone, peptide-nucleic acid backbone, polyamide, CH_2-NH-O-CH_2, CH_2-N(CH_3)-O-CH_2, CH_3-O-N(CH_3)-CH_2 , CH_2-N(CH_3)-N(CH_3)-CH_2, and O-N(CH_3)-CH_2-CH_2.

6. (Original) The compound of claim 3 wherein the modified purine or pyrimidine moiety includes inosine.

7. (Original) The compound of claim 3 wherein the modified sugar moiety includes sugar mimetics comprising C_4 - C_8 cycloalkyl.

8. (Previously Amended): The compound of claim 3 wherein the modified 5' or 3' hydroxyl moiety is selected from the group consisting of C_{1-4} alkoxy, intercalating agent, peptide, enzyme, and ribozyme.

9. (Presently Amended): The compound of claim 3 wherein the modified 2' hydroxyl moiety is selected from the group consisting of ~~OH, SH, SCH_2, OCH_3, F, OCN, OCH_6 CH_3, OCH_3OCH_3, $OCH_3O(CH_2)_nCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, where n is from 1 to about 10;~~ C_1 to C_{10} lower alkyl, substituted lower alkyl, substituted lower alkaryl substituted lower aralkyl; Cl; Br; CN; CF_3; OCF_3; O, S, N-alkyl; O, S, N-alkenyl; $SOCH_3$; SO_2CH_3; ONO_2; NO_2; N_3; NH_2; heterocycloalkyl, alkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a cholesteryl group; a conjugate; a reporter group; an intercalator; and a group for improving the pharmacokinetic properties of an oligonucleotide as compared to an unmodified compound~~; and a group for improving the pharmacodynamic properties of an oligonucleotide as compared to an unmodified compound~~.

10. (Original) The compound of claim 1 wherein the base sequence of the oligonucleotide or analog thereof is selected from the group consisting of

5'- GCCCATCACCATCTCTTC - 3',

5'- ACACGGCATCATGAATCA - 3',

5'-CCAGGGGCCCGCTGGTTA-3',

5'-ACCAAATTTTATATTCTA-3',

5'-CAGGCCCATCACCATCAC-3',

5'-GCCCAGGCCCATCACCAT-3', and

5'-TCTCTGACACGGCATCAT-3'.

11. (Presently Amended) A composition for inhibiting expression of angiogenin comprising an effective amount of an oligonucleotide or analog thereof having a base sequence

complementary to a target portion of a nucleic acid encoding human angiogenin in a pharmaceutically acceptable carrier.

12. (Original) The composition of claim 11 wherein the base sequence of the oligonucleotide or analog thereof is selected from the group consisting of

5'- GCCCATCACCATCTCTTC - 3',

5'- ACACGGCATCATGAATCA - 3',

5'-CCAGGGGCCCGCTGGTTA-3',

5'-ACCAAATTTTATATTCTA-3',

5'-CAGGCCCATCACCATCAC-3',

5'-GCCCAGGCCCATCACCAT-3', and

5'-TCTCTGACACGGCATCAT-3'.

13. (Presently Amended): A compound for inhibiting expression of angiogenin having the formula:



wherein

X is selected from the group consisting of O, S, and C_{1-4} alkyl;

B is selected from the group consisting of adenine, guanine, cytosine, and thymine, selected such that the oligonucleotide has a complementary base sequence with a portion of a target nucleic acid strand coding for human angiogenin thereby inhibiting expression thereof;

R_1 is selected from the group consisting of H, C_{1-4} alkyl, intercalating agent, peptide, enzyme, and ribozyme;

R_2 is selected from the group consisting of H, OH, SH, SCH_2, OCH_3, F, OCN, OCH_2 CH_3, OCH_3OCH_3, $OCH_3O(CH_2)_p$ CH_3, $O(CH_2)_pNH_2$, O $(CH_2)_pCH_3$, where p is from 1 to about 10; C_1 to C_{10} lower alkyl, substituted lower alkyl, substituted lower alkaryl, substituted lower aralkyl; Cl; Br; CN; CF_3; OCF_3; O, S, N-alkyl; O, S, N-alkenyl; $SOCH_3$; SO_2CH_3; ONO_2; NO_2; N_3; NH_2; heterocycloalkyl, alkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a cholesteryl group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide as compared to an unmodified oligonucleotide; and a group for improving the pharmacodynamic properties of an oligonucleotide as compared to an unmodified oligonucleotide; and

n is 5 to 100.

14. (Original) The compound of claim 13 wherein the base sequence is selected from the group consisting of

5'- GCCCATCACCATCTCTTC - 3',

5'- ACACGGCATCATGAATCA - 3',

5'-CCAGGGGCCCGCTGGTTA-3',

5'-ACCAAATTTTATATTCTA-3',

5'-CAGGCCCATCACCATCAC-3',

5'-GCCCAGGCCCATCACCAT-3', and

5'-TCTCTGACACGGCATCAT-3'.

Claims 15-23 (Cancelled)

24. (Previously Amended): The compound of claim 5 wherein the phosphorothioate is selected from the group consisting of alkyl phosphorothioate, cycloalkyl phosphorothioate, and phosphorodithioates.

25. (Previously Amended): The compound of claim 8 wherein the intercalating agent is a substituted acridine.

26. (Previously Amended): The compound of claim 13 wherein the intercalating agent is a substituted acridine.

27. (Previously Amended): The compound of claim 25 wherein the substituted acridine is selected from the group consisting of 2-methoxy-6-chloro-9-pentylaminoacridine, N-(6-chloro-2-methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-3-aminopropanol, and N-(6 chloro-2-methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-5-aminopentanol.

28. (Previously Amended): The compound of claim 26 wherein the substituted acridine is selected from the group consisting of 2-methoxy-6-chloro-9-pentylaminoacridine, N-(6-chloro-2-methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-3-aminopropanol, and N-(6 chloro-2-methoxyacridinyl)-O-methoxydiisopropylaminophosphinyl-5-aminopentanol.

29. (New): The compound of claim 3, wherein the modified 2' hydroxyl moiety is selected from the group consisting of OH, SH, SCH_2, OCH_3, F, OCN, OCH_2CH_3, OCH_3CH_3, $OCH_3O(CH_2)_nCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, where n is from 1 to about 10.

30. (New): The compound of claim 3, wherein the modified 2' hydroxyl moiety is a conjugate.

31. (New): The compound of claim 3, wherein the modified 2' hydroxyl moiety is a group for improving the pharmacodynamic properties of an oligonucleotide as compared to an unmodified compound.

32. (New): The compound of claim 3, wherein the modified 2' hydroxyl moiety is a group for improving the pharmacokinetic properties of an oligonucleotide as compared to an unmodified compound.